Success Metrics

Clinical Success Rate
75.0%

Based on 3 completed trials

Completion Rate
75%(3/4)
Active Trials
0(0%)
Results Posted
67%(2 trials)
Terminated
1(25%)

Phase Distribution

Ph phase_1
1
25%
Ph phase_3
2
50%
Ph early_phase_1
1
25%

Phase Distribution

2

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Early Phase 1First-in-human
1(25.0%)
Phase 1Safety & dosage
1(25.0%)
Phase 3Large-scale testing
2(50.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

75.0%

3 of 4 finished

Non-Completion Rate

25.0%

1 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(3)
Terminated(1)

Detailed Status

Completed3
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
75.0%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (25.0%)
Phase 11 (25.0%)
Phase 32 (50.0%)

Trials by Status

terminated125%
completed375%

Recent Activity

0 active trials
Showing 4 of 4
completedphase_3

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

NCT05777174
terminatedphase_1

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

NCT04109482
completedphase_3

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

NCT05425719
completedearly_phase_1

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

NCT03962998

Clinical Trials (4)

Showing 4 of 4 trials
NCT05777174Phase 3

Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring

Completed
NCT04109482Phase 1

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Terminated
NCT05425719Phase 3

Pharmacokinetics and Safety of MB-102 (Relmapirazin) and the MediBeacon Transdermal GFR Measurement System in Evaluation of Kidney Function in Normal and Renal Compromised Subjects

Completed
NCT03962998Early Phase 1

Oral Administration of MB-102 Versus Dual Sugar Testing for Gut Permeability

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4